2025 Silent Capital Report now available. Where family offices and LPs are actually deploying. [Download for free →]
About usSign in

Lumira Ventures

WebsiteLinkedInTwittercbCrunchbase
Status
ACTIVE
Global HQ
Toronto, Canada
Countries of investment
  • United States
  • Canada
Investment stages
  • Seed
  • Series A
  • Series B
  • Series C
  • Growth
Industries
  • Biotechnology
  • Therapeutics
  • Medical Devices
  • Digital Health
  • Diagnostics
  • Life Sciences
About
Lumira Ventures is a North American life sciences venture capital firm with decades of experience investing in healthcare companies from seed through growth stages. The firm partners with management teams across therapeutics, medical devices, digital health, and consumer healthcare sectors. Lumira operates from offices in Toronto, Montréal, Vancouver, and Boston, leveraging its extensive network to maximize value and impact of its portfolio companies.
Min check size
$5M
Max check size
$20M
Fund size
NPS

Investment Thesis

Lumira Ventures focuses on partnering with mission-driven entrepreneurs to build transformative biomedical companies across the development continuum. They seek to back innovations in genomics, cell and gene therapy, bioengineering, and medical devices that deliver high-impact products for patients.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

The team at Lumira Ventures is led by Managing General Partner Peter van der Velden and a team of nine partners with decades of experience investing across the full biomedical value chain. Partners bring combined expertise across therapeutics, medical devices, digital health, and consumer healthcare, leveraging deep relationships with strategic pharma and medtech acquirers. The team has been investing in oncology and life sciences for nearly two decades, overseeing 50+ approved products and 10 IPOs across more than 100 companies funded.

Lumira Ventures Contacts Information

Primary contact

Team

Lu Han - Partner

Suman Rao - Principal

Gerry Brunk - Managing Director

Peter van der Velden - Managing General Partner

Nikhil Thatte - Partner

Jacki Jenuth - Partner and COO

Beni Rovinski - Managing Director

Danielle Karakas - Analyst

Isabelle Harris - Analyst

Vasco Larcina - CFO

Marc McCoy - Venture Clinician

Dahlia Abbott - Accounting/Office Manager

Daniel Hétu - Managing Director

Michael Leung - Controller

Marco Moya - IT Engineer

Theodore Witek - Special Advisor

Portfolio

Endotronix

OpSens

BardyDx

Engage Therapeutics

Aurinia Pharmaceuticals

Zymeworks

G1 Therapeutics

Alpha-9 Oncology

AmacaThera

Antiva Biosciences

Arclight Therapeutics

Axonis Therapeutics

BioTheryX

Bright Angel Therapeutics

Cadence Neuroscience

Cardiac Dimensions

Congruence Therapeutics

Corvia Medical

COUR Pharmaceuticals

Cyrano Therapeutics

Damona Pharmaceuticals

DEKA Biosciences

Edesa Biotech

Endogenex

enGene

Exact Imaging

GenEp

Histosonics

Iterion Therapeutics

Kisoji

Medexus

Nocion Therapeutics

Sound Blade Medical

Specific Biologics

SpectraWAVE

Thryv Therapeutics

Transposon Therapeutics

X4 Pharmaceuticals

XyloCor

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp